China Sky One Medical wins approval for Policresulen vaginal suppositories

China Sky One Medical, a fully integrated pharmaceutical company, has obtained approval from the State Food and Drug Administration in China for the production of Policresulen vaginal suppositories.

Policresulen vaginal suppositories are indicated for the treatment of cervical erosion, cervicitis, various vaginal inflammations resulting from bacteria, trichomoniasis or candidiasis, and for pressure ulcers due to vaginal pessary.

The active ingredient in Policresulen vaginal suppositories is Policresulen, a topical haemostatic and antiseptic. This new product will be available to consumers around June 2009.

Yan-Qing Liu, chairman and CEO of China Sky One Medical, said: We are very pleased to receive State Food and Drug Administration approval in a timely manner, which continues to enable us to benefit from the increasing medical consumption in China tied to new healthcare reforms and a rising middle class. We remain confident in our ability to identify drugs that have strong market potential that will enhance our portfolio.

China Sky One Medical engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company (TDR), Harbin First Bio- Engineering Company Limited (First), Heilongjiang Tianlong Pharmaceutical, Inc. (Tianlong) and Peng Lai Jin Chuang Pharmaceutical Company (”Jin Chuang”) the Company manufactures and distributes over-the-counter pharmaceutical products.